ITI Large & Mid Cap Fund
The scheme seek to generate long term capital appreciation by investing in equity and equity related securities of large cap & mid cap stocks.
Growthvine rating: 1/5 — ranked #33 of 41 in category.
Fund basics
| Category | Equity: Large & Mid Cap |
|---|
| NAV | ₹10.15 (as of 2026-11-13) |
|---|
| AUM | ₹691 Cr |
|---|
| Expense ratio | 2.05% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Alok Ranjan |
|---|
| Exit load | 0.5% for redemption within 3 months |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −20.53% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 120.8% of NIFTY LargeMidcap 250's upside and 120.2% of its downside.
Market cap allocation
| Large cap | 36.4% |
|---|
| Mid cap | 37.7% |
|---|
| Small cap | 25.9% |
|---|
Concentration
| Top 5 holdings | 11.4% |
|---|
| Top 10 holdings | 21.1% |
|---|
| Total holdings | 88 |
|---|
| Index overlap | 34.5% |
|---|
| Active share | 65.5% |
|---|
Top holdings
- ICICI Bank Ltd. — 2.5%
- ESDS Software Solution Limited — 2.5%
- Divis Laboratories Ltd. — 2.2%
- TVS Motor Company Ltd. — 2.1%
- Larsen & Toubro Limited — 2.1%
- Kotak Mahindra Bank Ltd. — 2.0%
- IndusInd Bank Ltd. — 2.0%
- LG Electronics India Limited — 2.0%
- State Bank Of India — 1.9%
- Sun Pharmaceutical Industries Ltd. — 1.8%
Top sectors
- Banking & Financial — 20.6%
- Automobile — 9.4%
- Pharma & Biotech — 7.9%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 5.5% | Q1 (Top) | #10 of 38 |
| 2025 | −1.3% | Q4 (Bottom) | #31 of 34 |